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Herpesvirus saimiri (HVS) is a g2-herpesvirus sharing genomic colinearity and a high degree of functional homology with HHV-8. To
begin exploring the correlates of HVS infectivity and neutralization, we designed and implemented a new reporter assay. Using this assay, we
could demonstrate that HVS neutralizing antibodies are present at high levels in naturally infected squirrel monkeys and are strongly induced
after pathogenic, experimental infection of common marmosets. Further, we demonstrated that viral entry is influenced by cellular
glycosaminoglycans and that, similar to HHV-8, soluble heparin is capable of blocking infectivity. We next cloned and characterized the
positional homologue of HHV-8 K8.1, HVS Orf51. N-glycosidase F treatment indicates that like K8.1, Orf51 is a glycoprotein. Found in the
viral particle, it localizes to the endoplasmic reticulum of expressing cells. Like K8.1, Orf51 could bind to agarose-conjugated heparin,
implicating this molecule in viral attachment to cells. These studies provide the groundwork for additional experiments into the role that this
protein may be playing in viral pathogenicity, persistence, and cell tropism.
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Herpesvirus saimiri (HVS) is a g2-herpesvirus found in
wild squirrel monkeys (Saimiri sciureus) where it causes
little apparent pathology (Desrosiers and Falk, 1982; Falk
et al., 1972). However, infection of various New World
primates by HVS causes an acute peripheral T cell lympho-
ma and lymphocytic leukemia (Wolfe et al., 1971). This
virus shares genomic colinearity and high sequence homo-
logy with human herpesvirus-8 (HHV-8), a recently de-
scribed g2-herpesvirus that is etiologically associated with
Kaposi’s sarcoma, Multicentric Castleman’s disease and
some primary effusion lymphomas (Cesarman et al., 1996;
Russo et al., 1996). In vitro, HVS is able to infect a variety
of epithelial cell lines and undergoes lytic replication in owl
monkey kidney (OMK) cells (Duboise et al., 1996). Further,
it is also able to infect several T cell lines and can induce
transformation of common marmoset, rabbit, and human
T cells (Damania et al., 1999; Duboise et al., 1998a, 1998b;
Jung et al., 1991; Whitehouse, 2003). This is in stark0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: robert_means@hms.harvard.edu.contrast to the lack of a good lytic system for the study of
HHV-8. The presence of a lytic in vitro system and both
persistent and pathogenic animal models has established
HVS as a good model for studies of HHV-8.
Infection of cells by members of the herpesviridae
family can be broken down into multiple steps, viral
attachment to the cell surface followed by fusion and entry.
Viral attachment to the cell surface is likely not as simple
as a single viral protein binding to a single cellular
receptor. Rather, for a number of the herpesviruses, there
is an initial attachment to the cell through binding to
heparan-sulfate-containing proteoglycans or other glycosa-
minoglycans (GAGs) (Shukla and Spear, 2001). This is
followed by the binding of specific receptors that allow the
fusion and entry steps. The HHV-8 K8.1 protein has been
shown to interact with cell-surface heparan sulfate and this
interaction likely contributes to the broad cell tropism of
HHV-8 (Birkmann et al., 2001; Wang et al., 2001). HVS
encodes the Orf51 gene in a similar genomic location;
however, little study has been made of this gene or its role
in HVS cell entry. In addition to the Orf51 protein, HVS
expresses homologues of several other glycoproteins that
have been shown to be important in herpesvirus entry,
including glycoprotein B (gB), gH, gL, gM, and gN
(Ensser et al., 2003). These proteins act to bind the
Fig. 1. Overview of the HVS-SEAP infectivity assay. (A) HVS engineered
to carry the SEAP gene is used to infect susceptible target cells at different
M.O.I. After approximately 3 days, supernatant is collected and the amount
of SEAP activity determined by a chemiluminescent assay. (B) Subcon-
fluent OMK cells were infected with increasing amounts of either
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and cause fusion either at the cell surface or within endo-
somes (Spear and Longnecker, 2003). Coexpression of the
HHV-8 gB, gH, and gL homologues is sufficient to
mediate fusion between the expressing cell and a limited
number of epithelial or B cell targets; however, additional
viral glycoproteins might be necessary for high-level viral
infection. Little is known about the mechanisms of HVS
entry, the cell-surface molecules that the virus uses as
receptors or even which viral proteins mediate cell binding
and fusion.
To begin exploring the mechanisms of HVS entry, we
have designed and implemented a new infectivity assay
utilizing a virally encoded reporter gene. This assay was
used to look at the prevalence of neutralizing antibodies
against HVS, the dependence of HVS on GAGs and to
begin to explore the role of the Orf51 protein in virus–cell
interactions. We have cloned and characterized the Orf51
gene of the HVS C488 strain. It was found to be expressed
as a virally incorporated glycoprotein capable of binding to
heparan sulfate. Further, it was found that HVS depends on
cell-surface GAGs for its entry into cells, but may possess
both Orf51-dependent and -independent entry mechanisms.
These results should pave the way for future animal studies
to determine the role of Orf51 in vivo and to a better
understanding of the mechanisms of the herpesvirus entry
process.
HVSDSTP/SEAP (x) or HVSDTip/SEAP virus (n). At 3 days postinfec-
tion, the amount of SEAP activity in the medium was determined as
described in Materials and methods. This graph represents the average of
three experiments with the same viral stocks and the standard deviations are
indicated. CPS, counts per second; d.p.i., days postinfection.Results
Virally encoded SEAP can be used to measure infectivity
Little is known about the requirements for HVS infec-
tion of cells. To explore the mechanisms of viral entry, a
new infectivity assay was developed utilizing recombinant
HVS expressing secreted, engineered alkaline phosphatase
(SEAP) under the control of a HCMV promoter. Infection
of susceptible cells results in production of SEAP and
secretion into the medium where levels can be measured
using a sensitive chemiluminescent assay capable of dis-
criminating between engineered and endogenous alkaline
phosphatase (Fig. 1A). Two different viruses had been
previously constructed, HVS DSTP/SEAP and HVS
DTIP/SEAP (Duboise et al., 1996, 1998b) using a cloning
procedure dependent on the detection of SEAP. These
viruses had been shown to be competent for establishing
a persistent infection of common marmosets, but not for
inducing lymphoma (Duboise et al., 1998b). Owl monkey
kidney (OMK) cells are capable of supporting high-level
HVS lytic replication. To determine whether SEAP pro-
duction by these viruses could be used to measure the
amount of input virus, OMK cells were infected with
increasing amounts of virus. Additional cultures were
mock-infected in parallel. Measurement of the amount of
SEAP activity in the medium at 3 days postinfectionshowed a direct correlation between the amount of input
virus and the resulting SEAP activity (Fig. 1B). Measure-
ment of SEAP activity in the mock-infected cultures
showed a low background of 500 CPS or less for all of
the cultures tested (data not shown). Several stocks of virus
were thus tested and although the specific amount of SEAP
activity per microliter of virus differed between the stocks,
a linear relationship between the amount of input virus and
the amount of SEAP activity in the medium was always
observed (data not shown).
Naturally infected squirrel monkeys produce neutralizing
antibodies against HVS
Blood was taken from six squirrel monkeys (S. sciureus,
Ss) and tested for the presence of anti-HVS antibodies using
ELISA plates coated with purified HVS C488 virus grown in
OMK cells. As positive controls, two common marmosets
(Callithrix jacchus, Cj), another New World primate, experi-
mentally infected with HVS were tested and as a negative
control, a Cj that was naı¨ve for HVS was used. Of these
animals, four Ss tested highly positive for the presence of
anti-HVS antibodies, with detectable titers greater than
1:1000, comparable to the titers seen in the HVS-positive
Table 1
ELISA measurement of anti-HVS C488 titers
Serum source Serum dilution
1:20 1:200 1:1000
Ss 389-98 1.812 1.061 0.168
Ss 430-95 1.712 0.696 0.416
Ss 450-95 1.650 1.055 0.301
Ss 324-97 0.199 0.027 0.007
Ss 89-99 0.082 0.029 0.032
Ss 428-95 2.190 0.923 0.450
Uninfected Cj () 0.035 0.021 0.018
Cj 191-95 (+) 2.129 0.809 0.324
Cj 192-95 (+) >2.500 1.102 0.674
Sera from six Ss and three control Cj were tested against purified HVS
C488 coated onto Maxisorb plates as described in Materials and methods.
Optical density at 405 nm is reported for each dilution.
Fig. 2. Neutralization of HVS infectivity. Equal amounts of HVSDSTP/
SEAP were incubated with sera from the indicated animal for 1 h. Treated
virus was added to the wells of a 12-well plate containing subconfluent
OMK cells. At 3 days postinfection, the amount of SEAP activity in the
medium was determined as described in Materials and methods. The
percent infectivity was determined by dividing the relative SEAP activity
for each well by the amount of SEAP activity resulting from infection of
cells with mock-treated virus.
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titers of anti-HVS antibodies, greater than 1:20, but less than
1:200 and one animal, Ss 89-99, had only very weakly
detectable antibodies, even at a 1:20 dilution (Table 1).
We next tested whether sera from these animals had
detectable neutralizing antibodies against HVS. This was
done using a modified version of the infectivity assay. In
brief, virus was incubated for 1 h with heat-inactivated serum
from each of the animals at a 1:20 final dilution. After
incubation, the virus and antibody mixture was overlaid on
to OMK cells and the amount of SEAP activity in the
medium was measured at 3 days postinfection. One set of
wells was left uninfected to serve as background controls.
Wells containing virus incubated in the absence of sera or in
the presence of sera from a normal, uninfected Cj, were used
as negative controls. As a positive control, serum from two
Cjs experimentally infected with HVS were used. After
measurement, the values for each of the replicates were
averaged and the SEAP activity found in the background
wells was subtracted from each of the other wells. The values
were then divided by the amount of activity found in the well
incubated with virus alone to reach a percent infectivity
value, with the value of the control wells being 100%. Sera
from each of the Ss showing high levels of anti-HVS anti-
bodies also were able to almost completely neutralize viral
infectivity (Fig. 2). Ss 324-97, which had low levels of anti-
HVS antibodies, was not able to neutralize viral infectivity,
while Ss 89-99, with borderline detectable levels of anti-
bodies, reduced HVS infectivity by approximately 30% (Fig.
2). As expected, serum from the uninfected Cj showed no
ability to reduce HVS infectivity while sera from the infected
animals almost completely neutralized HVS infectivity (Fig.
2). These data demonstrate the utility of this new assay for
measuring not only infectivity, but also for testing antiviral
compounds.
GAGs influence HVS cell entry
Many of the other herpesviruses require cell-surface
GAGs for high-level infection. To test whether HVS hadsuch a requirement, Chinese hamster ovary (CHO) cells with
specific defects in GAG production pathways were utilized
as target cells for infection by the HVS DSTP/SEAP virus.
These cells have been previously used to demonstrate the
necessity of GAGs for infection of herpes simplex virus type
1, an a-herpesvirus (Shieh et al., 1992; Shukla et al., 1999).
The cell lines were created through ethylmethanesulfonate
treatment of the parental CHO cell line (Esko, 1992; Esko et
al., 1985, 1987, 1988; Lidholt et al., 1992). The PGSA-745
cell line lacks serine-1,3-D-xylosyltransferase, which adds
the first sugar in GAG production (Esko et al., 1985). The
PGSB-618 cell line lacks galactosyltransferase I and the
PGSD-677 cell line lacks both N-acetylglucosaminyltrans-
ferase and glucuronyltransferase (Esko et al., 1987, 1988;
Lidholt et al., 1992). These mutations block the production
and cell-surface expression of GAGs including heparan
sulfate. Infection of wild-type CHO cells with HVS, while
less efficient than OMK cells, resulted in an increase in
SEAP activity that directly correlated with the amount of
input virus (Fig. 3A). In contrast, infection of the three CHO
lines deficient in GAG production showed no increase in
Fig. 3. HVS utilizes GAGs for cell entry. (A) Various concentrations of
HVSDSTP/SEAP were used to infect the indicated wild-type or GAG-
production defective CHO cell lines. At 3 days postinfection, the amount of
SEAP activity in the medium was determined as described in Materials and
methods. Symbols: wild-type cells (.); PGSA-745 cells (x); PGSB-618
cells (n); PGSD-677 cells (E). (B) Equal amounts of HVSDSTP/SEAP
were incubated with either heparin or chondroitin sulfate at the indicated
concentrations for 1 h. Treated virus was added to the wells of a 12-well
plate containing subconfluent OMK cells. Mock-treated virus was added at
the same time. Six hours postinfection, either heparin or chondroitin sulfate
was added to the cultures containing the mock-treated virus. On the
following day, the media was replaced in all of the wells. After two
additional days, the amount of SEAP activity in the medium was
determined as described in Materials and methods. The percent infectivity
was determined by dividing the relative SEAP activity for each well by the
amount of SEAP activity resulting from infection of cells with mock-treated
virus and treatment with the same concentration of compound. Symbols:
chondroitin sulfate (n); heparin (.).
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(Fig. 3A). These data indicate that HVS, like several other
herpesviruses, can utilize GAGs for entry into cells.
HVS entry can be blocked with soluble heparin
To further explore the reliance of HVS on GAGs for
entry, we tested whether soluble heparin, structurally similar
to heparan sulfate, was capable of blocking virus entry into
OMK cells. A constant amount of virus, which had been
previously shown to give SEAP activity levels at least 10-
fold over background, was incubated with various amounts
of heparin for 1 h before infection of OMK cells. As a
control for effects of heparin on the OMK cells, an addi-
tional set of virus was mock-treated and used to infect OMK
cells. Six hours postinfection, heparin at the same concen-tration as was used for neutralization was added to the
mock-treated cultures. As a control for the specificity of
heparin, another set of virus was treated with chondroitin
sulfate or mock-treated, with chondroitin sulfate being
added 6 h after infection. One day postinfection, the
medium on all cultures was changed and the cells were
incubated for an additional 2 days before SEAP measure-
ment. The amount of SEAP activity in the medium was
normalized to the amount of SEAP activity in the medium
of cells that were infected with mock-treated virus. At high
heparin concentration, there was a dramatic decrease in viral
infectivity and this inhibition declined with decreasing
amounts of heparin (Fig. 3B). Interestingly, however, low
concentrations of heparin enhanced viral infectivity (Fig.
3B), an effect that has been seen with at least one other
herpesvirus, human herpesvirus 7 (Secchiero et al., 1997).
This neutralizing effect was specific because high levels of
chondroitin sulfate had no effect on infectivity. Taken
together with the decrease in infection of CHO cells
deficient for GAG production, these data indicate that
HVS likely utilizes cell-surface heparan sulfate for one step
of entry into cells.
The cloning of C488 Orf51
Little is known about the roles that the HVS glycopro-
teins play in viral entry. HVS is closely related to HHV-8,
where it is known that the K8.1 gene product binds to cell-
surface heparan sulfate. We therefore reasoned that the
positional homologue of K8.1, the Orf51 gene, might play
a role in viral infectivity by binding to cell-surface heparan
sulfate. The Orf51 gene is near the center of the HVS C488
L-DNA region from base 72626 to base 73436. It codes for
a protein of 269 amino acids containing nine potential N-
linked glycosylation sites and a putative 17 amino acid
(a.a.) transmembrane domain (Fig. 4A). Additionally, the
first 16 a.a. encode a potential signal sequence. As a source
of viral DNA, OMK were infected with HVS strain C488
and incubated until cultures began to show CPE at approx-
imately day 5 postinfection. Total cellular DNA was
extracted and used for PCR amplification of the Orf51
gene using primers that introduced restriction sites into the
termini to facilitate cloning into the pEF-myc/his expression
vector. After cloning and sequencing, this plasmid was used
for PCR amplification of a fragment of the Orf51 gene
encoding the first 240 a.a. up to the transmembrane domain.
This PCR product was cloned into the pQE-40 vector and
used to generate His6-tagged Orf51 protein in E. coli.
Protein was purified using a Ni2+ chelate affinity column
as described in Materials and methods and used to immu-
nize rabbits for antibody production. Lysates taken from
293T HEK cells transfected with the pEF-Orf51 plasmid
showed the presence of a diffuse band running at approx-
imately 52 kDa after Western blotting with the resulting
polyclonal anti-Orf51 rabbit sera (Fig. 4B, lane 2), while
this was not observed in lysates taken from cells transfected
Fig. 4. Characterization of Orf51. (A) Sequence of Orf51 highlighting the locations of the potential signal sequence at the N-terminus, nine potential N-linked-
glycosylation sites, and a transmembrane domain near the C-terminus. (B) The pEF-Orf51 or empty pEF vector plasmids were transfected into 293T HEK cells
as described in Materials and methods. Approximately 40 h later, cells were harvested, lysed in Lamelli buffer, and resolved on an 8% SDS-PAGE gel. Proteins
were then subjected to Western blot detection using a 1:2500 dilution of anti-Orf51 polyclonal sera. (C) The pEF-Orf51 or empty pEF vector plasmids were
transfected into 293T HEK cells and harvested as described above. Samples were boiled for 5 min in the presence of SDS and h-mercaptoethanol as described
in Materials and methods. An excess of NP-40 buffer either containing 10 U of N-glycosidase F (+ lane) or without enzyme ( lane) was added and the mixture
incubated for 3 h at 37 jC. After treatment, 25 Al of the mixture was analyzed by Western blotting using the anti-Orf51 antibody as described. The arrows
indicate the shift in molecular weight resulting from treatment.
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same molecular weight was observed when the same blot
was stripped and reprobed with an anti-His antibody (data
not shown). This apparent weight was higher than the 28-
kDa molecular weight predicted by the protein sequence.
Combined with the diffuse nature of the band and the
presence of nine potential N-linked glycosylation sites in
the amino acid sequence, we suspected that the altered
mobility was due to the posttranslational addition of N-
linked carbohydrate moieties.
Orf51 is a glycoprotein
The glycosylation status of Orf51 was examined by
treating 293T HEK cell-produced protein with N-glycosi-
dase F, an enzyme capable of removing N-linked glycans.
Cells were lysed in SDS buffer and the lysates were boiled
in the presence of h-mercaptoethanol. NP-40 and the N-
glycosidase F were then added. After incubation with this
enzyme, Orf51 ran as a sharp band of f27 kDa, the
predicted molecular weight of the nonglycosylated protein
(Fig. 4C). The change in molecular weight, about 25 kDa,
suggests that all nine potential N-linked glycosylation sites
are likely utilized, assuming a molecular weight of approxi-
mately 2.5 kDa per N-linked glycan.Expression of Orf51 during viral infection
Infection of OMK cells by HVS results in lytic produc-
tion of virus. Using the anti-Orf51 polyclonal rabbit sera, we
examined the production of Orf51 protein at various times
postinfection. Cells were infected with a high M.O.I. of
HVS C488 and harvested at various times postinfection.
Equal amounts of protein were analyzed for Orf51 expres-
sion by Western blotting. By 2 days postinfection (d.p.i.),
Orf51 protein was readily detectable and the amount of
protein increased throughout the 5 days the cultures were
monitored (Fig. 5A). Examination of the cultures infected in
parallel by immunoflourescent microscopy revealed Orf51
production in a small percentage of cells by 1 d.p.i. with
increasing numbers expressing protein at subsequent time
points (Fig. 5B). To explore the intercellular localization of
Orf51, we transfected 293T HEK cells with either the empty
pEF vector or the pEF-Orf51 construct and 2 days post-
transfection they were fixed, permeabilized, and stained
with the anti-Orf51 antisera. Cells were additionally stained
with antibodies against the ER resident protein phospho-
diester isomerase (PDI). Examination of these cells by
confocal microscopy revealed that the anti-Orf51 antibodies
specifically recognize a protein in the pEF-Orf51 transfected
cells, which localizes to the nuclear membrane and to a
Fig. 5. Expression and localization of HVS Orf51. (A) OMK cells in 10-cm dishes were infected with 10 M.O.I. of wild-type HVS C488. At the indicated days
postinfection (d.p.i.), cells were harvested, normalized for total protein content, and analyzed by Western blot for the presence of Orf51 protein. (B) OMK cells,
in Lab-Tek II chamber slides, were infected with 10 M.O.I of HVS C488 and incubated for various periods of time as indicated. Cells were then washed, fixed
with 4% paraformaldehyde, and permeabilized as described in Materials and methods. Orf51 localization was visualized by indirect immunofluorescence using
the anti-Orf51 antibody at a 1:100 dilution and a Texas Red anti-rabbit antibody (Red) at 1:5000. At time 0, cells were stained with a fluorescent green,
lipophilic dye to show the monolayer. (C) 293T HEK cells seeded in Lab-Tek II chamber slides were transfected with the pEF-Orf51 or empty pEF vector.
Approximately 36 h posttransfection, cells were fixed and permeabilized as described in Materials and methods. Orf51 localization was visualized by indirect
immunofluorescence using the anti-Orf51 antibody at a 1:100 dilution and an Alexa 486 anti-rabbit antibody (Green) at 1:5000. Additionally, the localization of
PDI was visualized by staining cells with an anti-PDI antibody at a 1:250 dilution followed by an anti-mouse Alexa 594 antibody (Red) at 1:2000.
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anti-PDI antibodies (Fig. 5C and data not shown). Parallel
cultures of pEF or pEF-Orf51 transfected cells were stained
with antibodies against the myc epitope tag that was
introduced onto the carboxyl terminus of the Orf51 protein
during cloning. Confocal imaging of these cells revealed a
pattern of staining that was similar to the one obtained when
using the anti-Orf51 antibody (data not shown).
Orf51 is a virion protein
Because we hypothesized that Orf51 was playing a role
in viral entry, it follows that it should be present within the
viral particle. As a test of this theory, we purified virus and
utilized it for ELISA testing of the anti-Orf51 polyclonal
rabbit serum. ELISA was performed with normal rabbit
serum, serum from a rabbit inoculated with purified, heat-
inactivated HVS C488, and the anti-Orf51 polyclonal se-
rum. As expected, no significant reactivity was observed
with the normal rabbit serum while the anti-HVS C488
serum showed strong reactivity even at a 1:16,000 dilution
(data not shown). The anti-Orf51 serum was stronglypositive at a 1:1000 dilution, but had little or no reactivity
at a 1:2000 dilution (data not shown). These data suggested
that Orf51 was indeed a virion protein.
To further confirm the presence of Orf51 in the viral
particle, we next subjected the virion preparations to
Western blot analysis with the anti-Orf51 polyclonal sera.
Supernatant from HVS C488 infected OMK cells was
harvested at 7 d.p.i. when lysis of infected cells was almost
complete and spun at low speed to remove cell debris.
Cleared supernatant was then subjected to filtration (0.4 Am)
and centrifugation at 13,000  g for 1 h to pellet the virions.
Pelleted virions were resuspended in buffer and column-
purified over Sepharose 4B resin. Eluted virions were
pelleted again and resuspended in 0.5% Triton X-100. As
a control, HHV-8 was purified in parallel from the super-
natant of TPA-stimulated BCBL-1 cells. Equal amounts of
HVS and HHV-8 purified virion proteins were boiled in
sample buffer containing SDS and h-mecaptoethanol and
proteins were separated by SDS-PAGE. The presence of
either Orf51 protein or the HHV-8 K8.1 protein in each
preparation was determined by Western blotting with the
appropriate polyclonal antibody. As expected, the K8.1
Fig. 7. Orf51 binds heparin-agarose. 293T HEK cells in 10-cm dishes were
transfected with either the pEF-Orf51 expression vector or the empty pEF
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rations (Fig. 6, right panel). While detection was weaker, we
observed a clear band at approximately 52 kDa in the HVS
preparation after blotting with the anti-Orf51 antibody (Fig.
6, left panel). We also observed a large, smeared band at a
higher molecular weight that may be due to higher order
oligomers of Orf51 that were not disassociated by boiling
under denaturing conditions.
Orf51 can bind to heparan sulfate
The K8.1 protein of HHV-8 is capable of binding to
heparan sulfate molecules (Birkmann et al., 2001; Wang et
al., 2001). To determine if HVS Orf51 also had this property
and potentially contributed to the ability of HVS to enter
into cells, we performed precipitations using heparin bound
to agarose beads. As a source of protein, 293T HEK cells
were transfected with either pEF-Orf51 or the empty pEF
vector. At 36 h posttransfection, cells were harvested and
lysed in NP-40-containing buffer. Lysates were subjected to
pull down with either agarose bead-conjugated heparin or
agarose beads alone. Analysis of the precipitated proteins by
Western blot revealed specific pull-down of Orf51 by the
heparan-sulfate-conjugated beads, but not unconjugated
beads (Fig. 7, lane 2 vs. lane 3). Further, the observed
reactivity was specific because no reactivity was seen when
heparan-sulfate-conjugated beads were used to immunopre-Fig. 6. HVS virion particles contain Orf51 protein. HVS C488 was column
purified as described in Materials and methods. In parallel, HHV-8 was
purified in a similar manner. Equal amounts of either HVS C488 (lanes 2
and 4) or HHV-8 (lanes 1 and 3) total protein were run out on an 8% SDS-
PAGE gel and examined by Western blot for the presence of Orf51 (left
panel) or K8.1 (right panel) using the appropriate antibodies. An arrow
indicates a band of protein at the appropriate molecular weight of Orf51.
vector. Approximately 36 h posttransfection, cells were harvested and lysed
in NP-40 buffer as described in Materials and methods. Each of the lysates
was subjected to immunoprecipitation using agarose-conjugated heparan
sulfate (Agarose-HS) or unconjugated agarose beads (Agarose). Precipitat-
ed proteins were next subjected to Western blotting with the anti-Orf51
polyclonal rabbit serum.cipitate proteins from pEF-transfected cells (Fig. 7, lane 1).
This indicates that Orf51 may be playing a role in viral
infection of cells by binding to cell-surface heparan sulfate
allowing virus to interact closely with the cell until the
fusion receptors are encountered.
HVS infectivity is not decreased by anti-Orf51 antibodies
Having documented a role for heparan sulfate in HVS
entry and an ability of Orf51 to bind the closely related
heparin, we next examined the ability of the polyclonal
anti-Orf51 serum to neutralize HVS infectivity. As was
done with the Ss and Cj sera described above, neutraliza-
tion assays were performed using a constant amount of
virus incubated with various concentrations of anti-Orf51
sera for an hour before infection onto OMK cells. As a
negative control, serum from a normal rabbit was used. The
neutralizing capacity of two additional sera were tested.
Polyclonal antibodies from a rabbit inoculated with puri-
fied, inactivated HVS particles and sera taken from a
common marmoset experimentally infected with HVS were
also tested. As expected, normal rabbit sera showed no
Fig. 8. Neutralization of HVS by various polyclonal sera. Equal amounts of
HVSDSTP/SEAP were incubated for 1 h with nine serial twofold dilutions
of the indicated sera starting at 10 Al. Treated virus was added to the wells
of a 12-well plate containing subconfluent OMK cells. At 3 days
postinfection, the amount of SEAP activity in the medium was determined
as described in Materials and methods. The percent infectivity was
determined by dividing the relative SEAP activity for each well by the
amount of SEAP activity resulting from infection of cells with mock-treated
virus.
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8). In stark contrast, both the sera from a rabbit inoculated
with HVS particles and the experimentally infected mar-
moset showed high neutralizing titers with 50% neutraliza-
tion of virus achieved with 0.06 Al and less than 0.04 Al of
serum, respectively (Fig. 8). However, no neutralization of
HVS activity was seen with the anti-Orf51 antibody at any
tested dilution (Fig. 8). This suggests that Orf51 might not
be playing a role in viral entry or that the virus has
additional mechanisms for infection that bypass the need
for Orf51.Discussion
In this report, we have demonstrated that HVS interacts
with cellular GAGs and that heparan sulfate is likely
playing a role in HVS entry. This result is not totally
unexpected. A number of other herpesviruses, including
members of all three subfamilies, utilize heparan sulfate to
differing degrees to aid in the entry process (Compton et al.,
1993; Herold et al., 1991; Jacquet et al., 1998; Laquerre
et al., 1998; Neyts et al., 1992; Shieh et al., 1992; Shukla
and Spear, 2001; Shukla et al., 1999; Spear et al., 1992;
WuDunn and Spear, 1989). Herpes simplex virus encodes
three different glycoproteins capable of binding to heparan
sulfate (Laquerre et al., 1998; Shukla et al., 1999). The
closely related g-herpesvirus, HHV-8, also utilizes heparan
sulfate as a target molecule to attach to cells. It does this
through at least two viral proteins, K8.1 and its gB
homologue (Akula et al., 2001; Birkmann et al., 2001;Wang et al., 2001). In addition, the HHV-8 gB protein also
acts to bind one of the viral receptors, a3h1 integrin,
through an RGD motif that is not found in the HVS gB
(Wang et al., 2003).
The mechanisms by which HVS enters into cells are
largely unclear. At a similar genomic location as gp350/220
in EBV, HVS encodes the Orf51 protein. The gB/gH/gL
glycoproteins of Epstein–Barr virus (EBV) cooperate with
gp350/220 and another glycoprotein, gp42, to mediate cell
entry. The gp350/220 protein binds to complement receptor
2 (CR2), also called CD21 (Nemerow et al., 1987; Tanner
et al., 1987). This binding to CR2 is followed by gp42
binding to HLA class II molecules, which then allows for
virus–cell fusion mediated by the gB/gH/gL glycoproteins
(Li et al., 1997). However, epithelial cells are largely CR2
deficient and the gp350/220 and gp42 proteins have been
shown to be dispensable with gH playing a greater role in
mediating attachment of virus to CR2 deficient cells (Janz
et al., 2000; Molesworth et al., 2000). Interestingly, the
amount of gp42 present in virus particles is regulated by
the viral producer cell, potentially regulating which target
cells can be infected (Borza and Hutt-Fletcher, 2002). In
this report, we have shown that Orf51 is able to bind to
heparan sulfate; however, this does not rule out an ability to
bind to a cell-surface protein in a manner similar to gp350/
220. Herpesvirus saimiri, like EBV, is able to infect both
lymphocytes and epithelial cells, so a producer cell effect is
possible. However, until a better system for studying the
role of the HVS viral glycoproteins is established, the
contribution of the individual glycoproteins will probably
remain occult.
Herpesvirus interactions with the glycosaminoglycans
has been proposed to allow for initial, relatively nonspe-
cific binding of the virus to target cells. This results in the
concentration of virus particles on the surface of these cells
and an increased likelihood of interactions between viral
proteins receptor proteins and their cognate ligands
(reviewed in Shukla and Spear, 2001). However, one of
the targets of HVS infection, T lymphocytes, posses only
low or undetectable amounts of heparan sulfate proteogly-
cans (Ibrahim et al., 1999; Manakil et al., 2001). This
suggests that the ability of HVS to bind to heparan sulfate
might play a larger role in its ability to enter into epithelial
cells and that other viral proteins are playing a role in
initiating viral interactions with the T lymphocytes. Alter-
natively, T cells possibly only express heparan-sulfate-
modified proteins in response to specific stimuli, such as
the up-regulation of proteoglycan syndecan-2 on human
macrophages in response to interleukin-1a (Clasper et al.,
1999). Binding to heparan sulfate might aid in viral
dissemination to T cells in another way. Nonspecific
attachment to the surface of nontarget cells such as APC,
which then interact with T cells, might serve to facilitate
the concentration and transfer of virus to susceptible
targets. Each of these possibilities needs to be explored
through further experimentation to fully evaluate the im-
R.E. Means / Virology 326 (2004) 67–78 75portance of heparan sulfate binding to HVS entry and
spread in vivo.
The results reported in this paper provide a good basis for
the further exploration of the role of GAGs in HVS entry.
While we have shown that HVS entry is decreased in cells
deficient for GAG production and that soluble heparin is
capable of blocking infectivity, this is not formal proof of
heparan sulfate proteoglycans acting as receptors for viral
entry. Several additional experiments would have to be
performed including treatment of target cells with hepar-
anases or sulfation-blocking chemicals like chlorate, fol-
lowed by an examination of their susceptibility to viral
infection. Additional experiments specifically removing
heparan sulfate binding proteins from the viral genome to
look at effects on infectivity would also address this
question and are currently being performed.
Heparan sulfate binding sequences are typically made up
of a series of basic residues, arginine, and lysine, separated
by nonbasic residues. Several different consensus sites have
been described including HSB sequence 1, XBBXBX,
HSB sequence 2, XBBBXXBX, and HSB sequence 3,
XBXBXXBX (B = basic, X = nonbasic) (Cardin and
Weintraub, 1989; Hileman et al., 1998; Sobel et al.,
1992). Examination of the Orf51 sequence reveals the
presence of at least one stretch of sequence rich in basic
residues and containing a consensus heparin binding site
starting with residue 214, SKHTNKLKPFKPKT
(XBBXXBXBXXBX BX, HSB sequence 3 underlined).
While this motif is longer than the published HSB sequence
3, it is unclear without further experimentation which
residues are critical to heparan sulfate binding. Given that
several of the herpesviruses have multiple proteoglycan
binding sequences, we are currently exploring whether the
HVS gB homologue is capable of binding to heparan
sulfate, potentially through a classical HSB domain that
has been identified in the ectodomain.
The Orf51 gene is a positional homologue of the K8.1
gene of KSHV. Other researchers have shown that KSHV
infection can be blocked by a-K8.1 antibodies. The
inability to block HVS infection with the anti-Orf51
antibody can be interpreted in several ways. First, there
is the possibility that Orf51 is dispensable for the infection
of certain target cells, yet required for the infection of
others, i.e., endothelial cells vs. T lymphocytes. Another
possibility is that although the antibody is capable of
recognizing native Orf51 protein, as evidenced by the
immunoflorescence data (Figs. 5B,C), critical neutralizing
epitopes might not be recognized. The Orf51 antibody was
raised against E. coli-produced protein, which is nongly-
cosylated and might not posses the same tertiary structure
as mammalian-derived protein. Therefore, the antiserum
used in this study may not recognize specific epitopes that
could potentially play a role in Orf51 interactions with
cell-surface target proteins. Yet, a third possibility is that
Orf51 is not playing a role in viral entry; rather, it may be
playing a role in viral assembly. To fully determine therole of Orf51 in viral entry, we are currently producing
HVS mutants lacking the Orf51 gene locus.
In addition to presenting the first detailed characteriza-
tion of a HVS glycoprotein, this report has demonstrated the
utility of the SEAP infectivity assay for investigating factors
effecting HVS entry into cells. With this assay, we have
demonstrated that naturally infected squirrel monkeys, in
which virus is apathogenic, make robust neutralizing anti-
body responses. Equally, in experimentally infected Cj
where the virus is invariably fatal, similarly robust
responses are made. This eliminates interference with or
direction of aberrant antibody production as a mechanism of
HVS pathogenicity in Cj. A number of other viruses such as
human immunodeficiency virus and its nonhuman primate
counterpart simian immunodeficiency virus both show a
similar pattern of increased pathogenicity upon zoonotic
transmission (Kaur et al., 1998; Mahy and Brown, 2000).
The question of what mechanism allows for apathogenic
infection of Ss still remains open and is potentially critical
in understanding the pathogenic mechanisms of other
viruses.
A better understanding of the entry mechanisms of the
herpesviruses is critical to devising antiviral vaccines and
prophylactic treatments. Defining common mechanisms that
multiple herpesviruses utilize, as well as how they differ,
could aid in the targeting of newly emerging pathogenic
herpesviruses. These results lay the groundwork for a more
intense study of the mechanisms by which HVS enters into
cells. Additionally, the presented data stresses the common
usage of heparan sulfate by the herpesviruses for entry,
suggesting possible avenues for new clinical modalities
targeting this potential Achilles heel.Materials and methods
Cell lines, sera, and transfections
The owl monkey kidney (OMK 637) cells have been
previously described (Simonds et al., 1975) and were
maintained in Modified Eagle’s medium (GIBCO BRL,
Grand Island, NY) supplemented with 10% fetal calf
serum (FCS) (GIBCO). The 293T HEK, Chinese hamster
ovary (CHO), PGSA-745 (CRL-2242), PGSB-618 (CRL-
2241), and PGSD-677 (CRL-2244) cells were obtained
from ATCC and maintained in Ham’s F12K medium
(GIBCO) supplemented with 10% FCS. BCBL-1 cells
were grown in RPMI 1640 supplemented with 10% FCS
and were induced for HHV-8 particle production through
the addition of 20 ng of phorbol-12-tetradecanoyl-13-
acetate (TPA) per milliliter as previously described (Yu
et al., 1999). Sera from common marmosets infected with
HVS and rabbits inoculated with purified, inactivated HVS
particles were the kind gift of Dr. Jae Jung (NEPRC,
Southborough, MA). Normal rabbit serum was purchased
from GIBCO.
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Transfectin reagent (Bio-Rad, Hercules, CA). Cells were
seeded into 10-cm dishes and grown untilf90% confluent,
at which point the medium was discarded and replaced with
10 ml of DMEM + 10% FCS. Two tubes per transfection
were prepared. Into tube 1, 15 Ag of DNA and 750 Al of
DMEM was added. To the second tube, 200 Al of DMEM
followed by 30 Al of Transfectin was added. The contents of
the two tubes were mixed, incubated for 20 min at room
temperature, and the overlaid on the 293T HEK cells. Cells
were incubated for 36–52 h in a humidified CO2 incubator
before harvest and analysis.
Whole-virus ELISA
The whole-virion enzyme-linked immunosorbent assay
(ELISA) procedure was performed as previously described
(Wyand et al., 1996). Briefly, HVS grown in tissue culture
was concentrated by ultracentrifugation and by Sepharose
chromatography (Pharmacia, Upsala, Sweden). Concentrat-
ed, purified virions were then disrupted in Triton X-100
detergent and used to coat flat-bottom 96-well plates (Max-
isorb, Nunc, Rochester, NY). Coated wells were incubated
with serially diluted serum samples, and bound antibodies
were detected with alkaline-phosphatase-conjugated sec-
ondary anti- human antibody (SouthernBiotech, Birming-
ham, AL). The amount of secondary was quantitated using
p-nitrophenyl phosphate substrate (SouthernBiotech, Bir-
mingham, AL) and measuring the optical density at 404
nm according to the manufacturer’s recommendations.
Infectivity and viral neutralization assays
Viral infectivity was measured utilizing the HVS DSTP/
SEAP and HVS DTip/SEAP viruses that have been
previously described (Duboise et al., 1996, 1998b).
OMK cells were plated into a 12-well dish and when just
subconfluent, infected with the indicated amount of virus
stock, containing approximately 1  107 infectious par-
ticles per milliliter, in a total of 1 ml of complete medium.
Three days postinfection, cell-free supernatant was har-
vested and the amount of alkaline phosphatase activity was
measured using the Great Escape SEAP reporter assay kit
(BD Biosciences, San Jose, CA) according to the manu-
facturer’s recommendations. Neutralization of viral infec-
tivity was measured in a similar fashion. Identical amounts
of virus, 0.5 Al containing approximately 5000 infectious
particles, were incubated for 1 h at 37 jC in 500 Al of
complete medium containing the indicated volume of
either potentially neutralizing serum or control serum.
Samples were then added to OMK in 12-well dishes
containing 500 Al of complete medium. SEAP activity
was measured as described above and the percent neutral-
ization was calculated by dividing the amount of SEAP
activity in the test well by the amount in the control well
containing the same dilution of serum.Orf51 cloning and antibody production
OMK cells were infected with the C488 strain of HVS.
Approximately 7 days postinfection, viral DNA was har-
vested and subjected to PCR amplification. The following
primers were used to amplify Orf51. BamHI-ORF51 5V: 5V-
AAGAATTCACCGCCATGAAGACTCAAGTTTTCTT-
TATTTGC-3V NotI-Orf51 3V: 5V-GCGGCCGCCACAAAA-
TATTCATTAAACTTTCG-3V.
The PCR product was cloned into the pEF vector
(Invitrogen, Carlsbad, CA) utilizing the unique BamHI
and NotI sites introduced during PCR amplification. After
complete sequencing to insure that no undesired mutations
had been introduced during PCR, this product was used for
the amplification of a fragment of the Orf51 gene, resulting
in the elimination of sequences coding for the potential
transmembrane domain. This PCR product was placed into
the pQE-40 vector (Qiagen, San Diego, CA) for expression
as a His6 tagged-protein. When E. coli XL-1 Blue cells
(Stratagene, La Jolla, CA) containing plasmid pQE40-Orf51
reached an optical density of approximately 0.6 at 600 nm,
1 mM isopropyl-b-D-thiogalactopyranoside was added; cells
were harvested 3 h after induction and then solubilized with
6 M guanidine hydrochloride. Due to the presence of the
affinity tail, His6-Orf51 protein was purified to virtual
homogeneity in one step by Ni2+ chelate affinity chroma-
tography. The purified recombinant His6-Orf51 protein was
used to generate polyclonal antibodies in New Zealand
White rabbits. A Ni2+ chelate affinity column containing
Orf51 protein was used to purify the antigen-specific anti-
bodies. Antibody specific for Orf51 was eluted with high
pH solution (0.1 M triethylamine [pH 11.5]).
N-glycosidase F treatment of Orf51
As a source of protein, 293T HEK cells were transfected
with the pEF-Orf51 plasmid by the calcium phosphate
method. Cell lysates were prepared by the addition of
20 Al of sample buffer containing 10% sodium dodecyl
sulfate (SDS) and 1% h-mercaptoethanol. Samples were
boiled for 5 min, and then a 180 Al of a solution containing
1% NP-40 and 1% mercaptoethanol was added. To this
mixture, 5 U of N-glycosidase F (Roche, Indianapolis, IN)
was added, and samples were incubated at 37 jC for 3 h. At
the end of the incubation period, the samples were electro-
phoresed in a 8% polyacrylamide-SDS gel and subjected to
Western blotting as described below.
Immunofluorescence
For immunolocalization of Orf51, A7 cells were seeded
into Lab-Tek II chamber slides (Nalge Nunc, Rochester,
NY) and transfected with pEF-Orf51 using Fugene 6
(Roche, Indianapolis, IN) according to the manufacturer’s
recommendations. Approximately 24 h posttransfection,
cells were washed three times with PBS and then fixed
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permeabilized with 0.1% Triton X-100 and then stained
with an anti-His monoclonal antibody (Santa Cruz Biotech)
followed by an Texas-Red-conjugated anti-mouse antibody
(Molecular Probes, Eugene, OR). Slides were visualized
using a Leica TCS SP laser-scanning microscope (Leica
Microsystems, Exton, PA). For visualization of Orf51 pro-
duction during HVS infection, OMK cells were seeded into
Lab Tek II chamber slides and infected with HVS C488 at a
M.O.I. of 10. At various times postinfection, cells were
washed three times with PBS and fixed for 30 min in PFA.
As above, cells were permeabilized and stained with the
anti-Orf51 antibody followed by staining with a Texas-Red-
conjugated anti-rabbit antibody (Molecular Probes).
Heparan sulfate precipitation and Western blotting
Orf51-transfected cells were harvested and lysed with
lysis buffer (0.15 M NaCl, 1% Nonidet P-40, 50 mM Tris
[pH 7.5]) containing 0.1 mM Na2VO3, 1 mM NaF, and
protease inhibitors (leupeptin, aprotinin, phenylmethylsul-
fonyl fluoride, and bestatin). For precipitation, 30 Al of
agarose conjugated-heparan sulfate (Sigma, St. Louis, MO)
or unconjugated agarose beads (Sigma) were added to the
cell lysate and incubated at 4 jC with gentle rocking for 3 h.
The samples were washed 3 times with lysis buffer, resus-
pended in Lamelli buffer and boiled for 5 min For Western
blot detection of proteins, precipitates or whole cell lysates
were electrophoresed through a 8% polyacrylamide-SDS gel
and transferred onto Immobilon-P membranes (Millipore,
Bedford, MA). The membranes were blocked with 5% skim
milk in phosphate-buffered saline–0.05% Tween 20 for 1 h.
The blots were then incubated sequentially with a 1:1000
dilution of anti-His antibody or 1:2500 dilution of anti-Orf51
sera followed by the appropriate secondary reagents. Anti-
body localization was visualized using a PicoWest chemilu-
minescence kit (Pierce, Rockford, IL) and a LAS-1000
charge-coupled device camera (Fuji, Inc., Tokyo, Japan).
Viral pellets and immunoprecipitation
To pellet virus, 1 ml of supernatant from either HVS
C488-infected OMK cells or TPA-induced, BCBL-1 cells
was spun for 3 h at 13,000  g in a refrigerated centrifuge.
The supernatants were discarded, and the pellets were
resuspended in 30 Al of Lamelli buffer. Each sample was
then subjected to two rounds of boiling for 5 min followed
by vortexing for 1 min and then subjected to Western
blotting with the indicated antibodies.Acknowledgments
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